BMS IM136003-Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Grants and Contracts Details

StatusFinished
Effective start/end date5/15/14 → 4/30/16

Funding

  • Bristol Myers Squibb Company: $12,456.00